The all-in-one platform helps entrepreneurs, clinics, med spas, gyms, and wellness brands launch cash-pay telehealth programs ...
Asianet Newsable on MSN
HIMS stock hits 2026 high after unlocking $400M working capital through JPMorgan — retail gets less bearish
The uncommitted facility provides Hims with a working-capital tool as it scales its healthcare and pharmacy operations.
Kennedy Jr.'s recent push to expand access to peptides, FDA career scientists determined there isn't adequate evidence to support any of the ones under consideration for production by compounding ...
The FDA has listed its advisory members for the committee that will discuss peptides in late July. Owais Durrani, DO, an emergency medicine physician in Houston, previously wrote for Healio that “some ...
The stock is already showing accelerating fundamentals (33% LTM revenue growth, 73% gross margin) plus credible weight-loss distribution via Novo Nordisk’s largest telehealth partner. The market is ...
U.S. FDA staff ​reviewers said there is little evidence to allow compounding pharmacies to manufacture seven popular peptides ...
The FDA staff’s view clashes with RFK Jr.’s push to deregulate peptides and move more of them toward Category 1 status.
Hone Health reports that 50% of peptide users mistakenly believe they take FDA-approved compounds, highlighting risks of ...
The health secretary has advocated for deregulating more peptides, but FDA scientists point to a lack of data about their ...
Kennedy Jr. has stacked another federal advisory panel with allies, advancing his efforts to force the Food and Drug ...
The U. Food and Drug Administration's staff reviewers said available evidence does not support allowing compounding ...
FDA revamps peptide panel by appointing wellness clinic physicians to advise on pharmacy compounding of seven peptides, including BPC-157 and TB-500.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results